Levocarnitine - PharmaKB

Levocarnitine

Carnitor, Levocarnitine (levocarnitine) is a small molecule pharmaceutical. Levocarnitine was first approved as Carnitor on 1985-12-27. It is used to treat deficiency diseases in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
nutritional and metabolic diseases	D009750

Trade Name

FDA

EMA

Carnitor, Carnitor sf, Levocarnitine, Levocarnitine sf (discontinued: Carnitor, Levocarnitine)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Levocarnitine

Tradename	Company	Number	Date	Products
CARNITOR	Leadiant Biosciences	N-018948 RX	1985-12-27	1 products, RLD, RS
CARNITOR	Leadiant Biosciences	N-020182 RX	1992-12-16	1 products, RLD, RS
CARNITOR	Leadiant Biosciences	N-019257 RX	1986-04-10	1 products, RLD, RS
CARNITOR SF	Leadiant Biosciences	N-019257 RX	2007-03-28	1 products, RLD

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
carnitor	New Drug Application	2024-10-30
carnitor sf	New Drug Application	2024-11-04
levocarnitine	ANDA	2025-07-17

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
deficiency diseases	EFO_1001067	D003677	E63

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

A: Alimentary tract and metabolism drugs

— A16: Other alimentary tract and metabolism products in atc

— A16A: Other alimentary tract and metabolism products in atc

— A16AA: Amino acids and derivatives

— A16AA01: Levocarnitine

HCPCS

Code	Description
J1955	Injection, levocarnitine, per 1 gm

Clinical

Clinical Trials

293 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv infections	D015658	EFO_0000764	B20	—	8	2	1	5	16
Fatigue	D005221	—	R53.83	—	4	6	1	5	15
Syndrome	D013577	—	—	—	6	3	1	5	13
Chronic kidney failure	D007676	EFO_0003884	N18.6	—	8	2	1	1	11
Male infertility	D007248	EFO_0004248	N46	1	2	—	1	6	9
Non-alcoholic fatty liver disease	D065626	EFO_0003095	K75.81	—	2	1	2	4	9
Peripheral nervous system diseases	D010523	—	G64	—	4	3	1	1	9
Fatty liver	D005234	EFO_0003934	—	—	2	1	2	3	8
Malnutrition	D044342	EFO_0008572	E40-E46	1	—	—	4	3	8
Peripheral arterial disease	D058729	EFO_0004265	—	2	—	2	2	—	6

Show 44 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Heart failure	D006333	EFO_0003144	I50	2	5	2	—	1	7
Type 2 diabetes mellitus	D003924	EFO_0001360	E11	—	3	1	—	1	5
Muscular atrophy	D009133	—	—	1	3	1	—	1	5
Diabetes mellitus	D003920	EFO_0000400	E08-E13	—	2	1	—	1	4
Dyslipidemias	D050171	—	—	—	2	1	—	1	4
Septic shock	D012772	—	A48.3	2	2	1	—	—	4
Spinal muscular atrophy	D009134	EFO_0003823	G12.1	1	3	1	—	—	4
Atrophy	D001284	—	—	1	3	1	—	—	4
Covid-19	D000086382	—	U07.1	—	2	1	—	1	3
Spasm	D013035	—	M62.83	—	—	1	—	2	3

Show 62 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Insulin resistance	D007333	EFO_0002614	E88.819	—	3	—	—	5	8
Autistic disorder	D001321	EFO_0003758	F84.0	—	2	—	—	1	3
Metabolic syndrome	D024821	EFO_0000195	E88.810	—	2	—	—	1	3
Brain injuries	D001930	—	S06.9	1	1	—	—	1	2
Atherosclerosis	D050197	EFO_0003914	I25.1	—	1	—	—	1	2
Keratoconjunctivitis sicca	D007638	EFO_1000906	—	—	1	—	—	1	2
Dry eye syndromes	D015352	—	H04.12	—	1	—	—	1	2
Patient compliance	D010349	—	—	—	1	—	—	1	2
Chronic fatigue syndrome	D015673	EFO_0004540	G93.31	—	1	—	—	1	2
Body weight	D001835	EFO_0004338	—	—	1	—	—	1	2

Show 42 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	2	—	—	—	5	7
Diet therapy	D004035	—	—	1	—	—	—	3	4
Cardiovascular diseases	D002318	EFO_0000319	I98	1	—	—	—	2	3
Mitochondrial diseases	D028361	EFO_0000591	—	1	—	—	—	2	3
Oligospermia	D009845	—	N46.1	1	—	—	—	1	2
Leukemia	D007938	—	C95	1	—	—	—	1	2
Epilepsy	D004827	EFO_0000474	G40.9	1	—	—	—	1	2
Drug resistant epilepsy	D000069279	—	—	1	—	—	—	1	2
Chronic progressive multiple sclerosis	D020528	EFO_0003840	—	1	—	—	—	—	1
Pancreatitis	D010195	EFO_0000278	K85	1	—	—	—	—	1

Show 15 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Brain diseases	D001927	—	G93.40	—	—	—	—	4	4
Glucose intolerance	D018149	HP_0000833	R73.03	—	—	—	—	3	3
Obesity	D009765	EFO_0001073	E66.9	—	—	—	—	3	3
Hyperlipidemias	D006949	EFO_0003774	E78.5	—	—	—	—	3	3
Weight loss	D015431	—	—	—	—	—	—	3	3
Hepatic encephalopathy	D006501	—	K72.91	—	—	—	—	3	3
Liver cirrhosis	D008103	EFO_0001422	K74.0	—	—	—	—	2	2
Overweight	D050177	—	E66.3	—	—	—	—	2	2
Humans	D006801	—	STY/T016	—	—	—	—	2	2
Culture media	D003470	—	—	—	—	—	—	2	2

Show 79 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Levocarnitine
INN	levocarnitine
Description	Carnitine is an amino-acid betaine that is butanoate substituted with a hydroxy group at position C-3 and a trimethylammonium group at C-4. It has a role as a human metabolite and a mouse metabolite. It is functionally related to a butyrate. It is a conjugate base of a carnitinium.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	C[N+](C)(C)C[C@H](O)CC(=O)[O-]